{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-019381","form_type":"8-K","ticker":null,"cik":"0001403708","company_name":"Evoke Pharma Inc","filed_at":"2024-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.073504+00:00","generated_at":"2026-06-05T16:52:06.745686+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evoke Pharma receives Nasdaq bid-price deficiency notice; 180-day cure until Aug 19, 2024","bullets":["On Feb 21, 2024, Nasdaq notified Evoke Pharma its stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2).","Company has until August 19, 2024 to regain compliance by closing at $1.00 or more for 10 consecutive business days.","No immediate effect on listing; stock continues to trade on Nasdaq under symbol 'EVOK'.","If not cured, company may qualify for an additional 180-day period if it meets other listing standards and considers a reverse stock split.","Failure to cure could lead to delisting; company intends to monitor and explore available options."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-019381","json":"https://secwatch.observer/filing/0000950170-24-019381.json","markdown":"https://secwatch.observer/filing/0000950170-24-019381.md","text":"https://secwatch.observer/filing/0000950170-24-019381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024019381/0000950170-24-019381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024019381/evoke-_nasdaq_notice_2.2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T16:52:06.745686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22049cdf16d1f1ca9c58e8ce94ee06ef96f4e6c6","claim":"Evoke Pharma Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"February 21, 2024, Evoke Pharma, Inc. (the “Company”) received a letter from the Nasdaq Stock Market staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until August 19, 2024, to regain compliance. The letter states that the Nasdaq staff will provide written notif","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024019381/0000950170-24-019381-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}